Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Alpha Heparin
2. Alpha-heparin
3. Heparin
4. Heparin Sodium
5. Heparin, Sodium
6. Heparin, Unfractionated
7. Heparinic Acid
8. Liquaemin
9. Unfractionated Heparin
1. (2s,3s,4r,5r,6r)-6-{[(2s,3s,4s,5r,6s)-6-{[(2r,3s,4s,5r)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic Acid
2. Hepflush
3. Chembl526514
4. Gtpl4214
5. S01xa14
6. Bdbm50480251
7. (2s,3s,4r,5r,6r)-3-[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2s,3s,4s,5r,6s)-6-[(2r,3s,4s,5r)-2-carboxy-4,6-dihydroxy-5-sulfooxyoxan-3-yl]oxy-2-hydroxy-4-(sulfomethyl)-5-sulfooxyoxan-3-yl]oxy-4,5-dihydroxyoxane-2-carboxylic Acid
1. 9005-49-6
Molecular Weight | 1039.9 g/mol |
---|---|
Molecular Formula | C26H41NO34S4 |
XLogP3 | -10.4 |
Hydrogen Bond Donor Count | 14 |
Hydrogen Bond Acceptor Count | 34 |
Rotatable Bond Count | 18 |
Exact Mass | 1039.0392821 g/mol |
Monoisotopic Mass | 1039.0392821 g/mol |
Topological Polar Surface Area | 589 Ų |
Heavy Atom Count | 65 |
Formal Charge | 0 |
Complexity | 2140 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 19 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Heparin sodium |
Drug Label | Intravenous solutions with heparin sodium (derived from porcine intestinal mucosa) are sterile, nonpyrogenic fluids for intravenous administration. They contain no bacteriostat or antimicrobial agent or added buffer. Edetate disodium, anhydrous is ad... |
Active Ingredient | Heparin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | 5,000 units/ml; 10,000 units/ml; 20,000 units/ml; 1,000 units/ml |
Market Status | Prescription |
Company | Hospira; Shenzhen Techdow; Sandoz; Pfizer; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms |
2 of 2 | |
---|---|
Drug Name | Heparin sodium |
Drug Label | Intravenous solutions with heparin sodium (derived from porcine intestinal mucosa) are sterile, nonpyrogenic fluids for intravenous administration. They contain no bacteriostat or antimicrobial agent or added buffer. Edetate disodium, anhydrous is ad... |
Active Ingredient | Heparin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | 5,000 units/ml; 10,000 units/ml; 20,000 units/ml; 1,000 units/ml |
Market Status | Prescription |
Company | Hospira; Shenzhen Techdow; Sandoz; Pfizer; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms |
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-05-09
Pay. Date : 2013-04-26
DMF Number : 17838
Submission : 2004-11-03
Status : Active
Type : II
Registration Number : 302MF10020
Registrant's Address : C/Antic Cami de Tordera, 109-119, Palafolls, 08389 Barcelona, Spain
Initial Date of Registration : 2020-01-31
Latest Date of Registration : --
NDC Package Code : 53484-001
Start Marketing Date : 2009-08-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9472
Submission : 1991-12-23
Status : Inactive
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5878
Submission : 1985-05-29
Status : Active
Type : II
NDC Package Code : 60870-0249
Start Marketing Date : 1980-04-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-09-15
Pay. Date : 2020-09-14
DMF Number : 2712
Submission : 1976-08-03
Status : Active
Type : II
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26680
Submission : 2013-01-07
Status : Active
Type : II
NDC Package Code : 53484-001
Start Marketing Date : 2009-08-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31738
Submission : 2017-05-17
Status : Active
Type : II
NDC Package Code : 53484-001
Start Marketing Date : 2009-08-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26680
Submission : 2013-01-07
Status : Active
Type : II
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : Complete
Rev. Date : 2013-05-09
Pay. Date : 2013-04-26
DMF Number : 17838
Submission : 2004-11-03
Status : Active
Type : II
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31738
Submission : 2017-05-17
Status : Active
Type : II
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9472
Submission : 1991-12-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5878
Submission : 1985-05-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-10-11
Pay. Date : 2022-08-16
DMF Number : 36291
Submission : 2021-09-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34686
Submission : 2020-03-17
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-07-16
Pay. Date : 2018-06-28
DMF Number : 9131
Submission : 1991-05-09
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-09-15
Pay. Date : 2020-09-14
DMF Number : 2712
Submission : 1976-08-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1007
Submission : 1966-11-01
Status : Inactive
Type : II
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
About the Company : Bioiberica is a global Life Science company with more than 45 years' experience in the production and development of molecules of high biological and therapeutic value for the phar...
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : Aspen API is the cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. With quality, compliance, and teamwork at its core, Aspen...
About the Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical indu...
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...
About the Company : Pfizer CentreOne® is an altogether different global contract development and manufacturing organization (CDMO), and a leading supplier of specialty APIs and intermediates.
...
About the Company : For more than 45 years, Bacto Chem has stood as a pioneer in the field of bio-pharmaceutical products and formulations. Established in 1972 in Hyderabad, Telangana, by the late D...
About the Company : Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediate...
About the Company : HELM Portugal is HELM’s Competence Centre for the marketing of Active Pharmaceutical Ingredients (API). The leading APIs distributed by Helm include Ascorbic Acid pharma Grade (C...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Defencath
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 19, 2024
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces New Commercial Agreement
Details : Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.
Brand Name : Defencath
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2024
Details:
The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: DefenCath
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: CorMedix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 28, 2024
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CorMedix
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
Details : The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.
Brand Name : DefenCath
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 28, 2024
Details:
Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Defencath
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: ARC Dialysis, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 08, 2024
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : ARC Dialysis, LLC
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
Details : Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.
Brand Name : Defencath
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 08, 2024
Details:
CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Nephrology Brand Name: Taurolock Hep500
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: RBC Capital Markets
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : RBC Capital Markets
Deal Size : $40.0 million
Deal Type : Public Offering
Details : CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.
Brand Name : Taurolock Hep500
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 28, 2023
Details:
Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.
Lead Product(s): Lidocaine,Heparin Sodium
Therapeutic Area: Urology Brand Name: Alenura
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Vaneltix Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Vaneltix Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Announces Enrolment of First Patient in a 4-Arm Clinical Trial of Alenura(TM)
Details : Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.
Brand Name : Alenura
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2023
Details:
DefenCath is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Defencath
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
Details : DefenCath is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous cathe...
Brand Name : Defencath
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 21, 2023
Details:
DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Defencath
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
Details : DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous ca...
Brand Name : Defencath
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2023
Details:
DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Defencath
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous ca...
Brand Name : Defencath
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 01, 2023
Details:
Defencath is available in Europe and other territories under the brand name Neutrolin. It is used for catheter-related bloodstream infections in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Defencath
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CorMedix Inc. Announces Regulatory and Manufacturing Updates
Details : Defencath is available in Europe and other territories under the brand name Neutrolin. It is used for catheter-related bloodstream infections in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.
Brand Name : Defencath
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2022
Details:
DefenCath is being developed as a catheter lock solution with an initial indication of use for the reduction of catheter-related bloodstream infections (CRBSIs) in patients with renal failure who are receiving chronic hemodialysis via a central venous catheter.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Defencath
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cormedix Inc. Announces Resubmission Of New Drug Application For DefenCath
Details : DefenCath is being developed as a catheter lock solution with an initial indication of use for the reduction of catheter-related bloodstream infections (CRBSIs) in patients with renal failure who are receiving chronic hemodialysis via a central venous ca...
Brand Name : Defencath
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 28, 2022
CAS Number : 9041-08-1
End Use API : Heparin Sodium
About The Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the...
CAS Number : 9041-08-1
End Use API : Heparin Sodium
About The Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the...
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CALCIPARINE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 25,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 18237
Regulatory Info : DISCN
Registration Country : USA
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Thrombophob Gel
Dosage Form : JEL
Dosage Strength : 20000IU/100g
Packaging : 25X1IU/100g
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : DISCN
Registration Country : USA
Brand Name : LIQUAEMIN SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 20,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 552
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : LIQUAEMIN SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 552
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : LIQUAEMIN SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 552
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : LIQUAEMIN SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 552
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : HEPARIN SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 552
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : HEPARIN SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 552
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : LIQUAEMIN SODIUM PRESERVATIVE FREE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1,000 UNITS/ML
Packaging :
Approval Date : 1986-04-11
Application Number : 552
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : LIQUAEMIN SODIUM PRESERVATIVE FREE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5,000 UNITS/ML
Packaging :
Approval Date : 1986-04-11
Application Number : 552
Regulatory Info : DISCN
Registration Country : USA
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
26 Oct 2024
Reply
14 Jun 2024
Reply
12 Jun 2024
Reply
22 Mar 2024
Reply
14 Mar 2024
Reply
18 Sep 2023
Reply
06 Jul 2023
Reply
17 Jun 2023
REF. STANDARDS & IMPURITIES
Heparin Sodium Molecular Weight Calibrant (10...
CAS Number : N/A
Quantity Per Vial :
Price ($) : 790
Catalog Number : 1304107
Current Lot : F0L483
Previous Lot :
NDC Code :
Heparin Sodium System Suitability (50 mg)
CAS Number : N/A
Quantity Per Vial :
Price ($) : 730
Catalog Number : 1304049
Current Lot : F0H211
Previous Lot :
NDC Code :
Heparin Sodium Identification (50 mg) (COLD S...
CAS Number : 9041-08-1
Quantity Per Vial :
Price ($) : 265
Catalog Number : 1304038
Current Lot : G2L413
Previous Lot : G1L413 (30-APR-2017)
NDC Code :
Heparin Sodium for Assays (9.5 mg) (COLD SHIP...
CAS Number : 9041-08-1
Quantity Per Vial :
Price ($) : 255
Catalog Number : 1304016
Current Lot : F0I187
Previous Lot :
NDC Code :
ANALYTICAL
Product Code : DL30S05-5008WT
Classification : Carbohydrates
Product Characteristics : G920107I
Category :
Description :
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?